Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Safety of 68Ga-NYM032 Injection PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer

NCT07649122 is registered in ClinicalTrials.gov with Norroy Bioscience Co., LTD as lead sponsor.

NCT NCT07649122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07649122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Safety of 68Ga-NYM032 Injection PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer
Lead sponsor
Norroy Bioscience Co., LTD
Phase
Phase 3
Overall status
Recruiting
Start date
August 31, 2026
Completion date
July 31, 2028
Enrollment
232 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer